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Abstract
Background: We present the case of a 52-year-old woman with depression who developed extrapyramidal
symptoms (mainly parkinsonism) and suicidal ideation while on fluoxetine.
Methods: The patient underwent neurological and neuroimaging examination.
Results: The patient’s neurological and neuroimaging examinations were normal and there was no other cause of
extrapyramidal symptoms. The patient showed remission of the aforementioned symptomatology when fluoxetine
was discontinued.
Conclusions: This case shows that fluoxetine can be associated with extrapyramidal symptoms, and this may have
an aggravating affect on clinical depression progress and the emergence of suicidal ideation.
Background
Extrapyramidal symptoms (EPSs) are an uncommon side
effect of serotonin reuptake inhibitors (SSRIs). Concomi-
tant use with antipsychotic medication or the presence
of other risk factors (age, gender) increase the vulner-
ability to EPSs [1]. The most common EPS associated
with SSRIs seems to be akathisia, followed by dystonia
and parkinsonism. Fluoxetine is the SSRI most asso-
ciated with extrapyramidal reactions in the majority of
cases [2,3]. Even, in adolescents treated with fluoxetine,
EPSs have been reported [4]. The symptoms are reversi-
ble with dose reduction, drug discontinuation, or by the
addition of another agent, such as anticholinergic
agents, b-blockers or benzodiazepines [5,6]. EPSs, and
especially akathisia, have been associated with the emer-
gence of suicidal ideation and suicidal acts in patients
receiving fluoxetine [7,8], however, a clear relationship
between fluoxetine and emerging suicidality is not cer-
tain [9].
We present the case of a female receiving fluoxetine
who, after approximately 1 month of therapy, developed
severe EPSs, mainly parkinsonism, with simultaneous
emergence of suicidal ideation.
Case presentation
A 52-year-old married woman presented to the emer-
gency department of the Psychiatric Clinic of ‘Attikon’
General Hospital in Athens with depressive symptoms.
The symptoms had begun 1 month prior to the referral
to our hospital, and included: depressive mood, insom-
nia, early morning waking, loss of appetite and psycho-
motor retardation. At that time she visited a private
psychiatrist, and was given antidepressant therapy with
fluoxetine, 60 mg per day and alprazolam 1.5 mg daily
for 4 weeks with no significant improvement. During
her examination, she was obviously very depressed and
anxious with no psychotic symptoms and she reported
suicidal ideation for the last 10 days.
Her neurological examination revealed severe rigidity
and bradykinesia. Her face was like a ‘mask’ and her
facial movements were almost non-existent. She was
speaking at low volume but she had no rest or move-
ment tremor, and no severe instability. Clinically,
although her treatment did not include any antipsycho-
tic drugs, her appearance did not differ from typical
antipsychotic-induced parkinsonism. Her husband had
observed reduced facial expression for the last 2 weeks.
The patient herself associated her suicidal ideation with
the subjective sensation of a progressive movement dis-
ability. Her medical history revealed no neurological* Correspondence: christo.christodoulou@gmail.com1Second Department of Psychiatry, Athens University Medical School,
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diseases. A magnetic resonance imaging (MRI) scan
showed no abnormal findings.
It was recommended that fluoxetine treatment be
stopped and alprazolam continued.
Results
At 1 week later the improvement of her rigidity and
bradykinesia was impressive. Her facial expression was
almost normal. The emotional distress was reduced and
surprisingly her suicidal ideation diminished with fluox-
etine withdrawal. At that time she was given another
class of antidepressant, showing significant improvement
of her depression.
Discussion
Considerable controversy exists regarding the relation-
ship between fluoxetine and the emergence of suicidal
ideation. Our patient had no neurological history. EPSs,
mainly parkinsonism, had appeared in the last 2 weeks
while she had been under medication with fluoxetine.
Several reports published in the 1990s suggested that
fluoxetine could be responsible for suicidal ideation or
behaviour [7,10-12]. More recent studies have suggested
this relationship as well. In a case-control analysis an
association has been found between SSRIs and suicide
events [13]. Moreover, a systematic review of rando-
mised controlled trials supports the relationship between
the use of SSRIs and the increased risk of suicidal beha-
viour. According to this review, such risk may be under-
estimated due to a number of methodological
limitations of the published reports [14].
By contrast, the results of a recent cohort study based
on a large sample do not support the hypothesis that
treatment with SSRIs increases the risk of suicide [15].
In another matched case-control study, the risk of suici-
dal behaviour was reported to be similar among users of
amitriptyline, fluoxetine and paroxetine [16]. Also, a
nationwide cohort study in Finland found that fluoxe-
tine was associated with a lower risk of suicide among
different classes of antidepressants. Moreover, the
results of the same study indicate that the current use
of any antidepressant among suicidal patients was asso-
ciated with increased risk of attempted suicide by self-
poisoning, but with a decreased risk of completed sui-
cide and death. The latter could be attributed to the
fewer cardiovascular and cerebrovascular side effects of
SSRI medication [17]. Finally, a meta-analysis of rando-
mised control trials of SSRIs conducted by pharmaceuti-
cal companies indicated that there is evidence of
increased risk of non-fatal self-harm in adults treated
with SSRIs but no evidence of increased risk of suicidal
thoughts [18].
Akathisia or dysphoric extrapyramidal reactions may
be a contributing factor to the emergence of suicidal
ideation during treatment with fluoxetine [19]. In our
case, parkinsonism and restlessness (but no akathisia)
were prominent in the clinical picture of the patient.
EPSs may have accidentally appeared in our patient, or
an underlying organic disorder may have predisposed
her to EPSs. However, an MRI scan revealed no abnor-
mal findings that could explain a possible vulnerability
to side effects. After stopping fluoxetine, the patient’s
extrapyramidal symptomatology improved dramatically
as did her suicidal thoughts. This report suggests that
severe EPSs, and in particular parkinsonism due to the
implicated movement disability, cause distress, which in
turn may cause suicidal ideation.
Conclusions
It is possible that SSRI as monotherapy could be the
cause of EPSs and subsequent suicidal ideation. Psychia-
trists must be aware of this side effect and be prepared
for clinical features characterised by movement disor-
ders in patients treated with SSRIs.
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